The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' (ARWR) triglyceride-buster hit the "best-case scenario" in two final-phase studies Wednesday, leading the stock to skyrocket. The biotech company's drug, plozasiran, reduced triglycerides by 79% and 81% in the yearlong studies, compared with just a 27% reduction in the placebo group. Patients also experienced what the company called an "unprecedented" 100% reduction in the risk of acute pancreatitis,…